Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinuclean DM
- Development stage
- Phase 4
- Lead developer
- Galsor
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Sinuclean DM is a nasal spray containing *Ecballium Elaterium*, developed by Galsor S.r.l. It is being investigated as a co-adjuvant to standard antibiotic therapy (amoxicillin/clavulanate) for the treatment of acute sinusitis. The goal of its use is to achieve faster symptom remission in patients with acute, subacute, or chronic sinusitis.
- Brand names
- SINUclean DM® Nasal SpraySinuclean DM Spray
Beyond the preview
Go deeper on Sinuclean DM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinuclean DM.